The agents that showed positive results for adjuvant treatment in selected patients with ccRCC ≥ pT3N0 of any grade included the ICI pembrolizumab and the vascular endothelial growth factor (VEGFR) inhibitor sunitinib (recommendation; LE: 1b; GR: A) (Choueiri et al. 2021a; Ravaud et al. 2016). This evidence concerns the gene KDR and nonpapillary renal cell carcinoma.